LATEST NEWS

  • Esteemed member of CurePSP's Board Leadership committee, Jeffrey S. Friedman MD, PhD, has been unanimously elected to the board of Celsense, Inc. Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents.

  • Cure PSP Grantee Rosa Rademakers will receive one of the most prestigious honors in neuroscience, the 2016 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases. She will be given the prize, which includes a $100,000 cash award, Monday during the 68th annual meeting of the American Academy of Neurology, in Vancouver, British Columbia. The prize also includes the opportunity to deliver a 20-minute lecture during the meeting.

  • EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 710 rare disease patient organisations in 63 countries. CurePSP is delighted to join with the voices of 30 million people affected by rare diseases throughout Europe to unite, expand and reinforce the rare disease movement of patient organisations and patient advocates around the world.

  • The Patrick Risha CTE (Chronic Traumatic Encephalopathy) Awareness Foundation is a Pennsylvania non-profit volunteer based organization. It was created in Patrick’s memory to help prevent CTE in future athletes and provide a resource for understanding the disease, how it is caused, and its relevance in youth sports.

  • This study will evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-98616, and assess the pharmacodynamics of BMS-986168 on cerebrospinal fluid (CSF) extracellular tau (eTau) concentrations in patients with PSP.

  • To participate, call the Janix Call Center at 702-487-0133, and refer to this study by its identifier: NCT02494024.